Literature DB >> 11306504

Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors.

A Hoos1, J J Lewis, C R Antonescu, M E Dudas, L Leon, J M Woodruff, M F Brennan, C Cordon-Cardo.   

Abstract

Desmoid tumors and fibrosarcomas (FS) are part of a wide spectrum of disordered fibroblastic growth that display striking clinical and phenotypic differences. This study was designed to characterize molecular abnormalities that are associated with these differences and to determine their clinical relevance. A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (HG) FS that were clinically and pathologically well characterized was analyzed for alterations in expression of Ki-67, Bcl-2, retinoblastoma gene product (pRB), and p53 by immunohistochemistry. LG-FS and HG-FS showed abnormal expression of Ki-67 (32 versus 86%), Bcl-2 (48 versus 57%), and pRB (56 versus 93%). In contrast, desmoid tumors showed a normal phenotype with these markers. p53 overexpression was identified in 20% of LG-FS and in 29% of HG-FS cases but only in 4% of desmoid tumors. There was an increasing trend in the proportion of abnormal expression of Ki-67, Bcl-2, pRB, and p53 with the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS. The molecular differences between tumor entities were highly statistically significant (P < 0.01). Significant associations between abnormal expression of pRB and recurrence-free survival of LG-FS patients (P = 0.05) and between Ki-67 overexpression and recurrence-free survival for tumors of >5 cm were observed (P = 0.02). The demonstrated differences of molecular alterations in HG-FS, LG-FS, and desmoids appear to be related to biological aggressiveness of such tumors, and they might be useful to differentiate between histologically similar cases of desmoid tumors and LG-FS. pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306504

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Presumption, privilege, and preemption.

Authors:  Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

2.  Immunohistochemical analysis of desmoid tumours.

Authors:  A Leithner; M Gapp; R Radl; A Pascher; P Krippl; K Leithner; R Windhager; A Beham
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

3.  Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors.

Authors:  A Hoos; M J Urist; A Stojadinovic; S Mastorides; M E Dudas; D H Leung; D Kuo; M F Brennan; J J Lewis; C Cordon-Cardo
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

Authors:  Axel Hoos; Alexander Stojadinovic; Bhuvanesh Singh; Maria E Dudas; Denis H Y Leung; Ashok R Shaha; Jatin P Shah; Murray F Brennan; Carlos Cordon-Cardo; Ronald Ghossein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors.

Authors:  Adelaide M Carothers; Hira Rizvi; Rian M Hasson; Yvonne I Heit; Jennifer S Davids; Monica M Bertagnolli; Nancy L Cho
Journal:  Cancer Res       Date:  2011-11-17       Impact factor: 12.701

6.  Papillary thyroid carcinoma with fibromatosis-like stroma: a report of two cases.

Authors:  Michiko Inaba; Shinobu Umemura; Haruhiro Satoh; Yasuko Ichikawa; Yosifumi Abe; Kiyoshi Kirokawa; Hideto Sakai; R Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 7.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

Review 8.  Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.

Authors:  Gabriel Wcislo; Katarzyna Szarlej-Wcislo; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-24       Impact factor: 4.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.